A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

ClinicalTrials.gov ID: NCT02440685

Public ClinicalTrials.gov record NCT02440685. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.

Study identification

NCT ID: NCT02440685
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Asana BioSciences; Industry
Enrollment: 51 participants

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2015 (Actual)
Primary completion: Jun 2018 (Actual)
Completion: Jul 2018 (Actual)
Last update posted: Jun 7, 2023

2015 – 2018

United States locations

U.S. sites: 12
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Arizona Oncology	Tempe	Arizona	85284	—
University of California, San Francisco	San Francisco	California	94143	—
Winship Cancer Institute - Emory	Atlanta	Georgia	30322	—
University of Michigan	Ann Arbor	Michigan	48109	—
START - Midwest	Grand Rapids	Michigan	49546	—
University of Mississippi Medical Center	Jackson	Mississippi	39216	—
Gabrail Cancer Center	Canton	Ohio	44718	—
Oregon Health & Science University	Portland	Oregon	97239	—
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	—
MD Anderson Cancer Center	Houston	Texas	77030	—
South Texas Accelerated Research Therapeutics	San Antonio	Texas	78229	—
Virginia Cancer Specialists	Fairfax	Virginia	22031	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02440685, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 7, 2023 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02440685 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →